Aventis returns Picovir to ViroPharma

AVE and VPHM mutually terminated their 2001 deal to co-develop and market VPHM's Picovir pleconaril to

Read the full 168 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE